Lambert Shiu Sells 501 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN - Get Free Report) CAO Lambert Shiu sold 501 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $282.88, for a total value of $141,722.88. Following the sale, the chief accounting officer now owns 32,969 shares in the company, valued at $9,326,270.72. The trade was a 1.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Penumbra Price Performance

Shares of PEN stock traded down $2.63 during trading hours on Friday, hitting $275.07. 347,006 shares of the company's stock were exchanged, compared to its average volume of 395,060. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The firm has a market cap of $10.59 billion, a P/E ratio of 809.01, a P/E/G ratio of 2.83 and a beta of 0.51. The firm has a 50 day moving average of $267.39 and a two-hundred day moving average of $235.44. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Sell-side analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PEN. True Wealth Design LLC acquired a new position in shares of Penumbra during the 3rd quarter worth approximately $26,000. UMB Bank n.a. increased its position in shares of Penumbra by 57.4% during the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $46,000 after purchasing an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new stake in shares of Penumbra during the fourth quarter worth approximately $56,000. Huntington National Bank increased its position in shares of Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after purchasing an additional 154 shares in the last quarter. Finally, Mather Group LLC. increased its position in shares of Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock worth $73,000 after purchasing an additional 208 shares in the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on PEN shares. Royal Bank of Canada upped their target price on Penumbra from $285.00 to $313.00 and gave the company an "outperform" rating in a research report on Wednesday, February 19th. Robert W. Baird upped their target price on Penumbra from $305.00 to $328.00 and gave the company an "outperform" rating in a research report on Wednesday, February 19th. Truist Financial upped their target price on Penumbra from $285.00 to $325.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Citigroup upped their target price on Penumbra from $220.00 to $245.00 and gave the company a "neutral" rating in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. upped their target price on Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $292.64.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.